­
­
­
­

Inventi Impact: Pharmacokinetics & Pharmacodynamics

Articles

  • Inventi:pkd/18560/16
    L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-release\nLevodopa/Carbidopa Tablets in Parkinsonâ??s Disease: A Randomised Study
    01-Jan-1970 Research 2016 : January - March
    Fabrizio Stocchi, Laura Vacca, Paola Grassini, Stephen Pawsey, Holly Whale, Stefano Marconi, Margherita Torti

    Objectives. To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent\ntablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating\nParkinson�s disease. Few studies assessed the pharmacokinetics of carbidopa to date. Methods. This was a single-centre, randomized,\ndouble-blind, double-dummy, two-period crossover study. Patients received V1512 (melevodopa 100 mg/carbidopa 25 mg) or L dopa\n100mg/carbidopa 25mg, 7 doses over 24 hours (Cohort 1), 4 doses over 12 hours (Cohort 2), or 2 doses over 12 hours in\ncombination with entacapone 200 mg (Cohort 3). Pharmacokinetic parameters included area under the plasma-concentration\ntime curve (AUC), maximum plasma concentration (

    How to Cite this Article
    CC Compliant Citation: Fabrizio Stocchi, Laura Vacca, Paola Grassini, et al., â??L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/\nCarbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study,â? Parkinson's Disease, vol.\n2015, Article ID 369465, 7 pages, 2015. doi:10.1155/2015/369465, http://creativecommons.org/licenses/by/3.0/.
    Download Full Text